Actual sales have shown a cyclic pattern with periods of decline and recovery. The CAGR over the last five years (2019-2023) is 0.41%, indicating stability starting to arise following significant declines in 2019 and 2020. The substantial increase in 2022 (56.67%) was a major rebound from previous lows. Year-on-year growth is projected to be stable at 4.26% into 2023, with sales expected to plateau at 4.9 million USD through 2028, suggesting no growth.
Future Trends: Watch for innovations in antiarrhythmic treatments and changes in healthcare policies that could disrupt this stability. Improved detection rates and new market entrants could also drive growth.
